e-therapeutics PLC's (LON: ETX.L) chairman Ali Mortazavi speaks to Proactive London's Andrew Scott after announcing they're to join forces with Belgian life sciences giant Galapagos to uncover a new means of treating idiopathic pulmonary fibrosis, a serious lung disease with a poor prognosis.
The work will focus on approaches to modulate one specific mechanism involved in IPF and other fibrotic conditions.